@First10EM @MicieliA_MD @thenntgroup @SZehtabchi Agree. What is the high-quality evidence that tPA is superior in efficacy for patient-oriented outcome? https://t.co/hCUdKUGJSU https://t.co/BnoxMrt2je
@gabe_fontaine @georgemastoras @CCREM2 @BMJ_EBM Not that odd considering a Cochrane SRMA states "there was no evidence to show that one thrombolytic agent was clearly better than another" (Wardlaw et al 2013). https://t.co/MekCQXoiOv
@_ericmckeon @TheSGEM @American_Heart @HeartandStroke @NightShiftMD @CAEP_Docs @EMSwami @jeremyfaust @CCREM2 @BMJ_EBM @ACEPNow @EddyLang1 @srrezaie @stemlyns Agree this is tricky. From basic science (as you show) a difference is plausible & should be e
@_ericmckeon @American_Heart @HeartandStroke @NightShiftMD @CAEP_Docs @EMSwami @jeremyfaust @CCREM2 @BMJ_EBM @ACEPNow @EddyLang1 @srrezaie @stemlyns Thank you for answering the questions and agreeing. We have common ground. SRMA 2013. Agree there are di
New from #CSO_Scotland https://t.co/w4v6R1J8O6 Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke
Cochrane Review http://t.co/PSnpsRXUK4 No evidence that one lytic agent better than another in CVA #FOAMed #emcritconf
@rfdsdoc @umanamd @Bodymender_n_ED cochrane review showed no difference btwn lyric agents http://t.co/CYJOtTr1gJ